Understanding the Clinical Burden and Prevalence of Lupus Nephritis

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Jorge Larranaga, MD

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.

Now Viewing

EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP: 2.Cost Drivers in Lupus Nephritis

EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources

EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment

EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice

Lupus nephritis (LN) is associated with considerable clinical and economic burdens in affected patients. Describe the clinical burden of LN on patients and their caregivers.
What are the current statistics on the prevalence and incidence of LN in different populations?
How many patients have systemic lupus erythematosus (SLE)?
How often do patients with SLE present with or develop LN?